Display options
Cite
Kearney K, Gold J, Corrigan C, et al. Chronic thromboembolic pulmonary hypertension in Australia and New Zealand: An analysis of the PHSANZ registry. Respirology. 2021;26(12):1171-1180doi: 10.1111/resp.14162.
Kearney, K., Gold, J., Corrigan, C., Dhital, K., Boshell, D., Haydock, D., McGiffin, D., Wilson, M., Collins, N., Cordina, R., Dwyer, N., Feenstra, J., Lavender, M., Wrobel, J., Whitford, H., Williams, T., Keating, D., Whyte, K., McWilliams, T., Keogh, A., Strange, G., Kotlyar, E., Anderson, J., & Lau, E. M. (2021). Chronic thromboembolic pulmonary hypertension in Australia and New Zealand: An analysis of the PHSANZ registry. Respirology (Carlton, Vic.), 26(12), 1171-1180. https://doi.org/10.1111/resp.14162
Kearney, Katherine, et al. "Chronic thromboembolic pulmonary hypertension in Australia and New Zealand: An analysis of the PHSANZ registry." Respirology (Carlton, Vic.) vol. 26,12 (2021): 1171-1180. doi: https://doi.org/10.1111/resp.14162
Kearney K, Gold J, Corrigan C, Dhital K, Boshell D, Haydock D, McGiffin D, Wilson M, Collins N, Cordina R, Dwyer N, Feenstra J, Lavender M, Wrobel J, Whitford H, Williams T, Keating D, Whyte K, McWilliams T, Keogh A, Strange G, Kotlyar E, Anderson J, Lau EM. Chronic thromboembolic pulmonary hypertension in Australia and New Zealand: An analysis of the PHSANZ registry. Respirology. 2021 Dec;26(12):1171-1180. doi: 10.1111/resp.14162. Epub 2021 Oct 05. PMID: 34608706.
Copy Download .nbib Format: NLM
Share it on

Respirology. 2021 Dec;26(12):1171-1180. doi: 10.1111/resp.14162. Epub 2021 Oct 05.

Chronic thromboembolic pulmonary hypertension in Australia and New Zealand: An analysis of the PHSANZ registry.

Respirology (Carlton, Vic.)

Katherine Kearney, Joshua Gold, Carolyn Corrigan, Kumud Dhital, David Boshell, David Haydock, David McGiffin, Michael Wilson, Nicholas Collins, Rachael Cordina, Nathan Dwyer, John Feenstra, Melanie Lavender, Jeremy Wrobel, Helen Whitford, Trevor Williams, Dominic Keating, Ken Whyte, Tanya McWilliams, Anne Keogh, Geoff Strange, Eugene Kotlyar, James Anderson, Edmund Mt Lau

Affiliations

  1. Heart and Lung Transplant Unit, St Vincent's Hospital Sydney, Sydney, New South Wales, Australia.
  2. University of New South Wales, Sydney, New South Wales, Australia.
  3. Liverpool Hospital, Sydney, New South Wales, Australia.
  4. Medical Imaging Department, St Vincent's Hospital Sydney, Sydney, New South Wales, Australia.
  5. Greenlane Cardiothoracic Surgical Unit, Auckland City Hospital, Auckland, New Zealand.
  6. Cardiothoracic Surgery, Alfred Hospital, Melbourne, Victoria, Australia.
  7. Macquarie University Hospital, Sydney, New South Wales, Australia.
  8. John Hunter Hospital, Newcastle, New South Wales, Australia.
  9. Department of Cardiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
  10. Sydney Medical School, University of Sydney, Camperdown, New South Wales, Australia.
  11. Cardiology Department, Royal Hobart Hospital, Hobart, Tasmania, Australia.
  12. Thoracic Medicine, The Prince Charles Hospital, Brisbane, Queensland, Australia.
  13. Advanced Lung Disease Unit, Fiona Stanley Hospital, Perth, Western Australia, Australia.
  14. School of Medicine, University of Notre Dame, Fremantle, Western Australia, Australia.
  15. Respiratory Medicine, Alfred Hospital, Melbourne, Victoria, Australia.
  16. Monash University, Melbourne, Victoria, Australia.
  17. Respiratory Medicine, Auckland City Hospital, Auckland, New Zealand.
  18. Respiratory Department, Sunshine Coast University Hospital, Birtinya, Queensland, Australia.
  19. Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

PMID: 34608706 DOI: 10.1111/resp.14162

Abstract

BACKGROUND AND OBJECTIVE: Chronic thromboembolic pulmonary hypertension (CTEPH) is a serious condition occurring in 2%-4% of patients after acute pulmonary embolism. Pulmonary endarterectomy (PEA) is a potential cure for technically operable disease. The epidemiology and long-term outcomes of CTEPH have not been previously described in Australia and New Zealand.

METHODS: Data were extracted from the Pulmonary Hypertension Society of Australia and New Zealand (PHSANZ) registry for patients diagnosed with CTEPH between January 2004 and March 2020. Baseline characteristics, treatment strategies, outcome data and long-term survival are reported.

RESULTS: A total of 386 patients were included with 146 (37.8%) undergoing PEA and 240 (62.2%) in the non-PEA group. PEA patients were younger (55 ± 16 vs. 62 ± 16 years, p < 0.001) with higher baseline 6-min walk distance (6MWD; 405 ± 122 vs. 323 ± 146 m, p = 0.021), whilst both groups had similar baseline pulmonary haemodynamics. Pulmonary hypertension-specific therapy was used in 54% of patients post-PEA and 88% in the non-PEA group. The 1-, 3- and 5-year survival rates were 93%, 87% and 84% for the PEA group compared to 86%, 73% and 62%, respectively, for the non-PEA group (p < 0.001). Multivariate survival analysis showed baseline 6MWD was an independent predictor of survival in both operated and medically managed patients.

CONCLUSION: In this first multicentre report of CTEPH in Australia and New Zealand, long-term survival is comparable to that in other contemporary CTEPH registries. However, PEA was only performed in a minority of CTEPH patients (37.8%) and significantly less than overseas reports. Greater awareness of PEA and improved patient access to experienced CTEPH centres are important priorities.

© 2021 Asian Pacific Society of Respirology.

Keywords: PHSANZ registry; chronic thromboembolic pulmonary hypertension; long-term survival; medical therapy; pulmonary endarterectomy; pulmonary hypertension

References

  1. Fedullo PF, Auger WR, Kerr KM, Rubin LJ. Chronic thromboembolic pulmonary hypertension. N Engl J Med. 2001 Nov 15;345(20):1465-72. - PubMed
  2. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D34-41. - PubMed
  3. Ende-Verhaar YM, Cannegieter SC, Noordegraaf AV, Delcroix M, Pruszczyk P, Mairuhu ATA, et al. Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature. Eur Respir J. 2017 Feb;1(2):49, 1601792. - PubMed
  4. Christian G, Mario G, Richard F, Pierre F, Peter D, Smriti S, et al. Microvascular disease in chronic thromboembolic pulmonary hypertension. Circulation. 2020 Feb 4;141(5):376-86. - PubMed
  5. Guérin L, Couturaud F, Parent F, Revel M-P, Gillaizeau F, Planquette B, et al. Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Thromb Haemost. 2014 Sep;112(9):598-605. - PubMed
  6. Pengo V, Lensing AWA, Prins MH, Marchiori A, Davidson BL, Tiozzo F, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004 May 27;350(22):2257-64. - PubMed
  7. Gall H, Hoeper MM, Richter MJ, Cacheris W, Hinzmann B, Mayer E. An epidemiological analysis of the burden of chronic thromboembolic pulmonary hypertension in the USA, Europe and Japan. Eur Respir Rev [Internet]. 2017 Mar 31 [cited 2020 May 1];26(143):160121. Available from: https://err.ersjournals.com/content/26/143/160121 - PubMed
  8. Kim NH, Delcroix M, Jais X, Madani MM, Matsubara H, Mayer E, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J [Internet]. 2019 Jan 1 [cited 2019 Dec 1];53(1):1801915. Available from: https://erj.ersjournals.com/content/53/1/1801915 - PubMed
  9. Ghofrani H-A, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013 Jul 25;369(4):319-29. - PubMed
  10. Ghofrani H-A, Simonneau G, D'Armini AM, Fedullo P, Howard LS, Jaïs X, et al. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respir Med. 2017 Oct;5(10):785-94. - PubMed
  11. Jaïs X, D'Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol. 2008 Dec;52(25):2127-34. - PubMed
  12. Kataoka M, Inami T, Kawakami T, Fukuda K, Satoh T. Balloon pulmonary angioplasty (percutaneous transluminal pulmonary angioplasty) for chronic thromboembolic pulmonary hypertension: a Japanese perspective. JACC Cardiovasc Interv. 2019 Jul 15;12(14):1382-8. - PubMed
  13. Jenkins D. Pulmonary endarterectomy: the potentially curative treatment for patients with chronic thromboembolic pulmonary hypertension. Eur Respir Rev. 2015 Jun 1;24(136):263-71. - PubMed
  14. Madani M, Mayer E, Fadel E, Jenkins DP. Pulmonary endarterectomy. Patient selection, technical challenges, and outcomes. Ann Am Thorac Soc. 2016 Jul 1;13(Suppl 3):S240-7. - PubMed
  15. Marion D, Irene L, Joanna P-Z, Pavel J, D'Armini AM, Repke S, et al. Long-term outcome of patients with chronic thromboembolic pulmonary hypertension. Circulation. 2016 Mar 1;133(9):859-71. - PubMed
  16. Cannon JE, Su L, Kiely DG, Page K, Toshner M, Swietlik E, et al. Dynamic risk stratification of patient long-term outcome after pulmonary endarterectomy: results from the United Kingdom National Cohort. Circulation. 2016 May 3;133(18):1761-71. - PubMed
  17. Corsico AG, D'Armini AM, Cerveri I, Klersy C, Ansaldo E, Niniano R, et al. Long-term outcome after pulmonary endarterectomy. Am J Respir Crit Care Med. 2008 Aug 15;178(4):419-24. - PubMed
  18. Matsuda H, Ogino H, Minatoya K, Sasaki H, Nakanishi N, Kyotani S, et al. Long-term recovery of exercise ability after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. Ann Thorac Surg. 2006 Oct 1;82(4):1338-43. - PubMed
  19. Condliffe R, Kiely DG, Gibbs JSR, Corris PA, Peacock AJ, Jenkins DP, et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med. 2008 May 15;177(10):1122-7. - PubMed
  20. Skoro-Sajer N, Marta G, Gerges C, Hlavin G, Nierlich P, Taghavi S, et al. Surgical specimens, haemodynamics and long-term outcomes after pulmonary endarterectomy. Thorax. 2014 Feb 1;69(2):116-22. - PubMed
  21. Wieteska M, Biederman A, Kurzyna M, Dyk W, Burakowski J, Wawrzyńska L, et al. Outcome of medically versus surgically treated patients with chronic thromboembolic pulmonary hypertension. Clin Appl Thromb Hemost. 2016 Jan 1;22(1):92-9. - PubMed
  22. Pepke-Zaba J, Delcroix M, Lang I, Mayer E, Jansa P, Ambroz D, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation. 2011 Nov 1;124(18):1973-81. - PubMed
  23. Saouti N, Morshuis WJ, Heijmen RH, Snijder RJ. Long-term outcome after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension: a single institution experience. Eur J Cardiothorac Surg. 2009 Jun 1;35(6):947-52. - PubMed
  24. Monaghesh E, Hajizadeh A. The role of telehealth during COVID-19 outbreak: a systematic review based on current evidence. BMC Public Health. 2020 Aug 1;20(1):1193. - PubMed
  25. Feinstein JA, Goldhaber SZ, Lock JE, Ferndandes SM, Landzberg MJ. Balloon pulmonary angioplasty for treatment of chronic thromboembolic pulmonary hypertension. Circulation. 2001 Jan 2;103(1):10-3. - PubMed
  26. Fukui S, Ogo T, Morita Y, Tsuji A, Tateishi E, Ozaki K, et al. Right ventricular reverse remodelling after balloon pulmonary angioplasty. Eur Respir J. 2014 May;43(5):1394-402. - PubMed
  27. Fukui S, Ogo T, Goto Y, Ueda J, Tsuji A, Sanda Y, et al. Exercise intolerance and ventilatory inefficiency improve early after balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension. Int J Cardiol. 2015 Feb 1;180:66-8. - PubMed
  28. Ogo T. Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension. Curr Opin Pulm Med. 2015 Sep;21(5):425-31. - PubMed
  29. Trip P, Nossent EJ, de Man FS, van den Berk IAH, Boonstra A, Groepenhoff H, et al. Severely reduced diffusion capacity in idiopathic pulmonary arterial hypertension: patient characteristics and treatment responses. Eur Respir J. 2013 Dec 1;42(6):1575-85. - PubMed
  30. Chandra S, Shah SJ, Thenappan T, Archer SL, Rich S, Gomberg-Maitland M. Carbon monoxide diffusing capacity and mortality in pulmonary arterial hypertension. J Heart Lung Transplant. 2010 Feb 1;29(2):181-7. - PubMed
  31. Benza RL, Gomberg-Maitland M, Elliott CG, Farber HW, Foreman AJ, Frost AE, et al. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies. Chest. 2019 Feb 14;156(2):323-37. - PubMed

Publication Types